Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,203 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Brighton Collaboration standardized template with key considerations for a benefit-risk assessment for the Comirnaty COVID-19 mRNA vaccine.
Pather S, Charpentier N, van den Ouweland F, Rizzi R, Finlayson A, Salisch N, Muik A, Lindemann C, Khanim R, Abduljawad S, Smith ER, Gurwith M, Chen RT; Benefit-Risk Assessment of VAccines by TechnolOgy Working Group (BRAVATO; ex-V3SWG). Pather S, et al. Among authors: smith er. Vaccine. 2024 Sep 17;42(22):126165. doi: 10.1016/j.vaccine.2024.126165. Epub 2024 Aug 27. Vaccine. 2024. PMID: 39197299 Free article. Review.
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of nucleic acid (RNA and DNA) vaccines.
Kim D, Robertson JS, Excler JL, Condit RC, Fast PE, Gurwith M, Pavlakis G, Monath TP, Smith J, Wood D, Smith ER, Chen RT, Kochhar S; Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG). Kim D, et al. Among authors: smith j, smith er. Vaccine. 2020 Jul 22;38(34):5556-5561. doi: 10.1016/j.vaccine.2020.06.017. Epub 2020 Jun 19. Vaccine. 2020. PMID: 32571717 Free PMC article. Review.
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of protein vaccines.
Kochhar S, Kim D, Excler JL, Condit RC, Robertson JS, Drew S, Whelan M, Wood D, Fast PE, Gurwith M, Klug B, Khuri-Bulos N, Smith ER, Chen RT; Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG). Kochhar S, et al. Among authors: smith er. Vaccine. 2020 Jul 31;38(35):5734-5739. doi: 10.1016/j.vaccine.2020.06.044. Epub 2020 Jul 9. Vaccine. 2020. PMID: 32653276 Free PMC article. Review.
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of inactivated viral vaccines.
Kochhar S, Excler JL, Kim D, Robertson JS, Fast PE, Condit RC, Drew S, Wood D, Gurwith M, Klug B, Whelan M, Khuri-Bulos N, Mallett Moore T, Smith ER, Chen RT; Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG). Electronic address: brightoncollaborationv3swg@gmail.com. Kochhar S, et al. Among authors: smith er. Vaccine. 2020 Sep 3;38(39):6184-6189. doi: 10.1016/j.vaccine.2020.07.028. Epub 2020 Jul 31. Vaccine. 2020. PMID: 32747214 Free PMC article.
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccines.
Condit RC, Kim D, Robertson JS, Excler JL, Gurwith M, Monath TP, Pavlakis G, Fast PE, Smith J, Smith ER, Chen RT, Kochhar S; Brighton Collaboration Benefit-Risk Assessment of Vaccines by Technology (BRAVATO) Working Group. Electronic address: bc-coordinator@taskforce.org. Condit RC, et al. Among authors: smith j, smith er. Vaccine. 2020 Nov 17;38(49):7708-7715. doi: 10.1016/j.vaccine.2020.08.009. Epub 2020 Sep 6. Vaccine. 2020. PMID: 32907759 Free PMC article. Review.
Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) standardized template for collection of key information for benefit-risk assessment of live-attenuated viral vaccines.
Gurwith M, Condit RC, Excler JL, Robertson JS, Kim D, Fast PE, Drew S, Wood D, Klug B, Whelan M, Mallett Moore T, Khuri-Bulos N, Smith ER, Chen RT, Kochhar S; Brighton Collaboration Viral Vector Vaccines Safety Working Group V3SWG. Gurwith M, et al. Among authors: smith er. Vaccine. 2020 Nov 17;38(49):7702-7707. doi: 10.1016/j.vaccine.2020.09.042. Epub 2020 Oct 16. Vaccine. 2020. PMID: 33070999 Free PMC article. Review.
Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment.
Custers J, Kim D, Leyssen M, Gurwith M, Tomaka F, Robertson J, Heijnen E, Condit R, Shukarev G, Heerwegh D, van Heesbeen R, Schuitemaker H, Douoguih M, Evans E, Smith ER, Chen RT; Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG). Custers J, et al. Among authors: smith er. Vaccine. 2021 May 21;39(22):3081-3101. doi: 10.1016/j.vaccine.2020.09.018. Epub 2020 Oct 3. Vaccine. 2021. PMID: 33676782 Free PMC article. Review.
A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for a soluble glycoprotein vaccine to prevent disease caused by Nipah or Hendra viruses.
Eldridge JH, Egan MA, Matassov D, Hamm S, Hermida L, Chen T, Tremblay M, Sciotto-Brown S, Xu R, Dimitrov A, Smith ER, Gurwith M, Chen RT; Benefit-Risk Assessment of VAccines by TechnolOgy Working Group BRAVATO, ex-V3SWG). Eldridge JH, et al. Among authors: smith er. Vaccine. 2021 Sep 7;39(38):5436-5441. doi: 10.1016/j.vaccine.2021.07.030. Epub 2021 Aug 7. Vaccine. 2021. PMID: 34373117 Free article. Review.
A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for an inactivated viral vaccine against Chikungunya virus.
Hernandez LM, Sumathy K, Sahastrabuddhe S, Excler JL, Kochhar S, Smith ER, Gurwith M, Chen RT; Benefit-Risk Assessment of VAccines by TechnolOgy Working Group (BRAVATO, ex-V3SWG). Hernandez LM, et al. Among authors: smith er. Vaccine. 2022 Aug 19;40(35):5263-5274. doi: 10.1016/j.vaccine.2022.06.006. Epub 2022 Jun 15. Vaccine. 2022. PMID: 35715351 Free PMC article. Clinical Trial.
Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment.
Folegatti PM, Jenkin D, Morris S, Gilbert S, Kim D, Robertson JS, Smith ER, Martin E, Gurwith M, Chen RT; Benefit-Risk Assessment of VAccines by TechnolOgy Working Group BRAVATO, ex-V3SWG). Folegatti PM, et al. Among authors: smith er. Vaccine. 2022 Aug 19;40(35):5248-5262. doi: 10.1016/j.vaccine.2022.06.008. Epub 2022 Jun 14. Vaccine. 2022. PMID: 35715352 Free PMC article.
1,203 results